Show simple item record

dc.contributor.authorMilosevic, Vladan
dc.contributor.authorEdelmann, Reidunn Jetne
dc.contributor.authorWinge, Ingeborg
dc.contributor.authorStrell, Carina
dc.contributor.authorMezheyeuski, Artur
dc.contributor.authorKnutsvik, Gøril
dc.contributor.authorAskeland, Cecilie
dc.contributor.authorWik, Elisabeth
dc.contributor.authorAkslen, Lars Andreas
dc.contributor.authorÖstman, Arne
dc.description.abstractPurpose: Angiogenesis is crucial for tumor growth and is one of the hallmarks of cancer. In this study, we analyzed microvessel density, vessel median size, and perivascular a-SMA expression as prognostic biomarkers in breast cancer. Methods: Dual IHC staining was performed where alpha-SMA antibodies were used together with antibodies against the endothelial cell marker CD34. Digital images of stainings were analyzed to extract quantitative data on vessel density, vessel size, and perivascular alpha-SMA status. Results: The analyses in the discovery cohort (n = 108) revealed a statistically significant relationship between large vessel size and shorter disease-specific survival (p = 0.007, log-rank test; p = 0.01, HR 3.1; 95% CI 1.3–7.4, Cox-regression analyses). Subset analyses indicated that the survival association of vessel size was strengthened in ER + breast cancer. To consolidate these findings, additional analyses were performed on a validation cohort (n = 267) where an association between large vessel size and reduced survival was also detected in ER + breast cancer (p = 0.016, log-rank test; p = 0.02; HR 2.3, 95% CI 1.1–4.7, Cox-regression analyses). Conclusion: Alpha-SMA/CD34 dual-IHC staining revealed breast cancer heterogeneity regarding vessel size, vessel density, and perivascular a-SMA status. Large vessel size was linked to shorter survival in ER + breast cancer.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleVessel size as a marker of survival in estrogen receptor positive breast canceren_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2023 the authorsen_US
dc.source.journalBreast Cancer Research and Treatmenten_US
dc.identifier.citationBreast Cancer Research and Treatment. 2023, 200, 293–304.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal